What are the adverse reactions during treatment with Lenvatinib? How should this be handled?

Lenvatinib is a multi-target tyrosine kinase inhibitor that is widely used to treat various types of cancer such as advanced hepatocellular carcinoma (HCC), thyroid cancer, and renal cell carcinoma. It inhibits tumor angiogenesis and cell proliferation by inhibiting a series of important tyrosine kinases, such as VEGFR (vascular endothelial growth factor receptor), FGFR (fibroblast growth factor receptor), PDGFR (platelet-derived growth factor receptor), etc. Although lenvatinib has significant efficacy in treatment, it is also accompanied by certain side effects, so close monitoring and corresponding treatment measures are required during use.

1. Common adverse reactions and treatments

（1) Hypertension

Lenvatinib may cause high blood pressure, a common side effect, and some patients may require medical intervention to control blood pressure. Blood pressure may rise significantly during the early stages of treatment. For patients with elevated blood pressure, it is recommended to use antihypertensive drugs, such as ACE inhibitors, calcium channel blockers, etc., to control blood pressure. If blood pressure is poorly controlled, the dose of lenvatinib may need to be adjusted or treatment withheld.

Processing method:

Monitor blood pressure regularly, especially during the first few weeks of treatment.

For patients who have developed high blood pressure, antihypertensive medications can be used to control blood pressure.

If blood pressure cannot be controlled, the dose may need to be reduced or discontinued, and treatment adjustments may be made under the guidance of a physician.

(2) Diarrhea

Diarrhea is one of the more common side effects of lenvatinib treatment. Diarrhea may lead to dehydration and electrolyte imbalance, affecting the patient's quality of life.

Processing method:

For diarrhea, patients can take symptomatic drugs such as antidiarrheal drugs.

Replenish fluids and electrolytes appropriately to prevent dehydration.

If diarrhea is severe or persistent, the need to reduce the dose or suspend the medication should be evaluated until symptoms are controlled.

(3) Fatigue and decreased appetite

Fatigue and decreased appetite are also common side effects of lenvatinib, which may affect patients' daily activities and quality of life. Fatigue and loss of appetite may be related to the antitumor effects of the drug, but may also be due to other side effects such as nausea or diarrhea.

Processing method:

Symptomatic and supportive treatment is provided, and patients are encouraged to maintain a good diet and rest.

If the loss of appetite is more severe, nutritional supplements may be needed.

If fatigue persists and affects daily life, you may consider adjusting the treatment plan.

2. Serious adverse reactions and treatment

(1) Abnormal liver function

Lenvatinib may cause abnormal liver function, especially in patients with already damaged livers, such as those with hepatocellular carcinoma. Damage to liver function may manifest as an increase in the levels of serum liver enzymes (such as AST, ALT), and may develop into liver failure in severe cases.

Processing method:

Liver function should be checked regularly during treatment, especially when starting treatment.

If liver function abnormalities occur, first consider discontinuing or reducing the drug and taking supportive care, such as correcting electrolyte imbalances or providing liver protection.

If liver function worsens significantly, the drug may need to be discontinued and continued treatment evaluated.

(2) Bleeding

Lenvatinib may increase the risk of bleeding, particularly in the presence of inhibition of angiogenesis. Symptoms of bleeding may include skin bruising, bleeding gums, blood in the stool, or vomiting blood.

Processing method:

If bleeding symptoms occur, discontinue medication immediately and initiate symptomatic treatment.

For mild bleeding, observation and supportive care may be required; for severe bleeding, emergency measures, such as blood transfusion or surgery, should be taken.

(3) Proteinuria and renal impairment

Lenvatinib may cause proteinuria and even renal damage in some patients. Proteinuria, which is the presence of abnormal protein in the urine, may be a sign of kidney damage.

Processing method:

Have regular urine tests, especially early in treatment.

If proteinuria or renal function abnormalities occur, treatment should be reduced or suspended according to the situation, and supportive treatment should be provided.

In severe renal impairment, medication may need to be stopped and other treatments recommended by your doctor.

3. Skin reaction

During treatment with lenvatinib, some patients may experience skin reactions, such as rash, dryness, hair loss, etc. Rashes often appear as erythema, itching, or dry skin and may affect patient comfort.

Processing method:

Mild skin reactions can be treated with topical medications, such as moisturizers or anti-allergy medications.

If the rash is severe or accompanied by other symptoms (such as fever), reduction or suspension of medication should be considered.

In case of severe skin reaction, you should seek medical treatment promptly and take appropriate treatment.

Lenvatinib, as a multi-target tyrosine kinase inhibitor, has good anti-tumor effects, but it is also associated with certain adverse reactions, especially hypertension, diarrhea, abnormal liver function and bleeding. Therefore, during treatment with lenvatinib, patients need to be closely monitored, including regular checks of blood pressure, liver function, urine and skin conditions. Once serious side effects occur, corresponding measures should be taken promptly and the drug dosage should be adjusted or discontinued if necessary. In addition, treatment under the guidance of a doctor can effectively reduce adverse reactions and ensure the safety and effectiveness of treatment.

Reference materials:https://www.lenvima.com/